An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age

Vaccine

Volumn 32, Issue 9, 2014, Pages 1121-1129

  Poder, Airi ^a   Simurka, Pavol ^b   Li, Ping ^c   Roy Ghanta, Sumita ^c   Vaughn, David ^c  

^a TARTU UNIVERSITY CLINICS   (Estonia)

^b FACULTY HOSPITAL   (Slovakia)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Adolescents; H1N1; Influenza; Pandemic; Vaccine

Indexed keywords

ADJUVANT; ADOLESCENTS; H1N1; INFLUENZA; PANDEMIC; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CHILD; DRUG COMBINATIONS; ESTONIA; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SINGLE-BLIND METHOD; SLOVAKIA; SQUALENE;

EID: 84895060626     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.031     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention (CDC). Updated CDC estimates of 2009 h1n1 influenza cases, hospitalizations and deaths in the United States, April 2009-April 10, 2010. Available at: [accessed 13.03.2012]. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
2. Shrestha S.S., Swerdlow D.L., Borse R.H., Prabhu B.S., Finelli L., Atkins C.Y., et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011, 52(S1):S75-S82.
3. Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, et al. Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe. Eur Surveill 2011;16(26):pii=19903. Available at: [accessed 01.11.2012]. http://www.eurosurveillance.org/ViewArticle.aspx%3FArticleId=19903.
4. Hardelid P., Andrews N.J., Hoschler K., Stanford E., Baguelin M., Waight P.A., et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010, 14:115-192.
5. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
6. Centers for Disease Control and Prevention (CDC) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:521-524.
7. Aranda-Romo S., Comas-Garcia A., Garcia-Sepulveda C.A., Hernandez-Salinas A.E., Pina-Ramirez M., Noyola D.E. Effect of an immunization program on seasonal influenza hospitalizations in Mexican children. Vaccine 2010, 28:2550-2555.
8. National Center for Immunization and Respiratory Diseases CDC, Center for Diseases Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep 2009;58:1-8.
9. Melidou A., Gioula G., Exindari M., Chatzidimitriou D., Diza-Mataftsi E. Influenza A (H5N1): an overview of the current situation. Eur Surveill 2009, 14:1e4.
10. Garcon N., Vaughn D., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012, 11:349-366.
11. A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435.
12. Nagai H., Ikematsu H., Tenjinbaru K., Maeda A., Dramé M., Roman F.P. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis 2010, 10:338.
13. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted Clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
14. Diez-Domingo J., Garces-Sanchez S., Baldo J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010, 29:e35-e46.
15. World Health Organization (WHO). Global Alert and Response (GAR). Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the October 2009 meeting of the Immunization Strategic Advisory Group of Experts, December 04, 2009. Available at: [accessed on 13.03.2012]. http://www.who.int/csr/disease/swineflu/meetings/sage_oct_2009/en/.
16. World Health Organization (WHO). WHO recommendations on pandemic (H1N1) 2009 vaccines. Pandemic (H1N1) 2009: briefing note 2. Available at: [accessed on 13.03.2012]. http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html.
17. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A) adjuvant: preliminary report of an observer-blind, randomized controlled trial. Vaccine 2010, 28:1740-1745.
18. Roman F., Clement F., Dewe W., Walravens K., Maes K., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011, 18:835-843.
19. Ikematsu H., Nagai H., Kawashima M., Kawakami Y., Tenjinbaru K., Maeda A., et al. Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010, 6:888-893.
20. Ikematsu H., Tenjinbaru K., Li P., Madan A., Vaughn D.W. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012.
21. Carmona A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Diessaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28:5837-5844.
22. Langley J.M., Reich D., Aggarwal N., Connor N., Lebel M.H., Gupta A., et al. Randomized, multicentre trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age. Pediatr Infect Dis J 2012, 31:848-858.
23. Saitoh A., Nagai A., Tenjinbaru K., Li P., Vaughn D.W., Roman F., et al. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Hum Vaccin Immunother 2012, 8:749-758.
24. European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007. Available at: [accessed on 13.03.2012]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003872.pdf.
25. Hehme N.W., Künzel W., Petschke F., Gisela T., Carmen R., Christian Van H., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-769.
26. US Food and Drug Administration (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available at: [accessed on 13.03.2012]. http://www.fda.gov/cber/gdlns/panfluvac.htm.
27. Garcia-Silicia J., Gillard P., Carmona A., Tejedor J.C., Aristegui J., Merino J.M., et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011, 29:4353-4361.
28. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children. J Am Med Assoc 2010, 303:37-46.
29. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
30. Yang W., Dionne M., Kyle M., Aggarwal N., Li P., Madariaga M., et al. Long-term immunogenicity of an AS03-adjuvanted influenza A (H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013, [Epub ahead of print]. 10.1016/j.vaccine.2013.07.007.
31. Oh C.E., Lee J., Kang J.H., Hong Y.J., Kim Y.K., Cheong H.J., et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010, 28:5857-5863.
32. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
33. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
34. Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to one year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatr Infect Dis J 2012 [Epub].
35. Schwarz T.F., Horacek T., Knuf M., Damman H.G., Roman F., Dramé M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290.
36. World Health Organization (WHO). Options for the use of human H5N1 influenza vaccines and the WHO H5N1vaccine stockpile. WHO Scientific Consultation; 2007 October 1-3; Geneva, Switzerland. Available at: [accessed on 13.03.2012]. http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf.
37. Stephenson I., Gust I., Pervikov Y., Kieny M.P. Development of vaccines against influenza H5. Lancet Infect Dis 2006, 6:458-460.
38. Ferguson M., Risi G., Davis M., Sheldon E., Baron M., Li P., et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012, 205:733-744.